The European Commission has recently announced a significant update regarding the use of indoxacarb in biocidal products, extending its approval period until 31 December 2026. This move ensures the continued use of indoxacarb, a key active substance, in product-type 18 biocidal products as per the standards set by Regulation (EU) No 528/2012.
Background of Indoxacarb's Approval
Originally sanctioned under Directive 98/8/EC, indoxacarb's role in the EU's pesticide landscape has been crucial, especially for product-type 18, which includes insecticides, acaricides, and other arthropod-controlling products. Commission Implementing Decision (EU) 2024/731 marks the latest in a series of extensions, allowing for a detailed renewal assessment process.
Renewal Process and Evaluation Challenges
The journey towards the renewal of indoxacarb's approval began with an application on 28 June 2018. The evaluation process, led by the French competent authority, highlighted the intricate nature of such assessments, focusing on the substance's reference specifications and investigating its endocrine-disrupting potential. This level of scrutiny underscores the EU's commitment to health and environmental safety.
Previous Extensions and Current Decision
Prior extensions, under Commission Implementing Decisions (EU) 2019/1030 and (EU) 2021/1287, aimed to provide ample time for a thorough review. The latest postponement to 31 December 2026, addresses unforeseen challenges in the evaluation, such as additional data requirements and the examination of new scientific evidence.
Impact of the Extension
This extension reflects the EU's dedication to maintaining a rigorous regulatory framework, balancing the need for effective biocidal products with the imperative to protect human health and the environment. By ensuring indoxacarb remains approved, subject to Annex I conditions of Directive 98/8/EC, the decision supports the needs of stakeholders relying on this active substance for their biocidal products.
